U.S. Preeclampsia Laboratory Testing Market Predicted to Flourish, Anticipating 5.1% CAGR Growth by 2026
The U.S. preeclampsia laboratory testing market is poised for substantial growth in the coming years, with a forecasted Compound Annual Growth Rate (CAGR) of 5.1% from 2021 to 2026. In 2020, the market recorded revenues of US$2,339.7 million, and this figure is expected to reach US$3,040.5 million by the end of 2026, with an estimated 4,629,000 women undergoing diagnostic tests.
Preeclampsia, a condition known to be the second leading cause of maternal mortality in the U.S., not only affects fetal and infant health but also poses a heightened risk of cardiovascular and metabolic diseases for both the mother and child later in life. The Centers for Disease Control and Prevention reports that preeclampsia occurs in about 1 in 25 pregnancies in the U.S., contributing to 15% of premature births. Despite the lack of a reliable predictive test or complete cure for the disease, increased awareness and early diagnosis can prevent maternal and neonatal deaths.
The growing health and economic burden of preeclampsia are driving demand for laboratory testing. According to the Preeclampsia Foundation, short-term medical costs related to preeclampsia amount to US$2.18 billion for the U.S. healthcare system. While mild and severe preeclampsia incidences are expected to contribute equally to market growth, severe preeclampsia is predicted to experience the highest growth rate by 2027.
Innovations in preeclampsia diagnostics are on the rise, with new product launches and research collaborations playing a pivotal role. Companies like DiabetOmics and Progenity have introduced novel diagnostic tests, addressing the need for early detection in high-risk pregnant women.
Government and academic institutions are also collaborating to improve diagnostics and find a cure for preeclampsia. Research funding from the National Institutes of Health (NIH), including institutes like the National Heart, Lung, and Blood Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is driving advancements in this field.
While urine tests currently lead in terms of market value and volume, blood tests are expected to witness stronger growth due to their need for early diagnosis and higher accuracy. Novel biomarkers and non-invasive early detection systems, like those being developed through collaborations between Thermo Fisher Scientific, Inc. and NX Prenatal, hold significant promise for improving maternal and fetal health.
Hospitals and clinics have been the primary contributors to revenue in the U.S. preeclampsia laboratory testing market. However, diagnostic centers are expected to experience the highest growth rate by 2027, thanks to the use of novel biomarkers and increased government and patient advocacy support for improved diagnostics.
On the flip side, a declining fertility rate and delayed parenthood are acting as restraints for the market. As more women delay childbirth or opt out of parenthood, coupled with a rise in infertility and lower birth rates, there is a decreased incidence of preeclampsia. This poses a challenge to the market’s growth.
Key players in the U.S. preeclampsia laboratory testing market include PerkinElmer Inc., F. Hoffmann-La Roche Ltd., ThermoFischer Scientific Inc., Siemens Healthineers AG, GestVision, Inc., Metabolomic Diagnostics Ltd., DiabetOmics Inc., and DRG INSTRUMENTS GMBH, among others.
U.S. Preeclampsia Laboratory Testing Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021-2026 – [2023 UPDATE Available – Forecast 2023-2030*] (By Test Type, Preeclampsia Type, End User, By Geography, Leading Companies) https://www.fairfieldmarketresearch.com/report/us-preeclampsia-laboratory-testing-market
Our Trending Reports:
Sperm Function Testing Market
Food Authenticity Testing Market
Genetic Toxicology Testing Market
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Fairfield Market Research
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
This press release first seen on Brilad